Welcome to Our Medtech Talk Podcast Channel

Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.

CEO John Pedersen Explains Why Urology – and Augmenix – Are Enjoying Such an “Interesting Time”

June 13, 2018

In this Medtech Talk Podcast, CEO John Pedersen explains why he chose to help Augmenix roll out its SPACEOAR implant, a hydrogel that’s inserted between a patient’s prostate and rectum to save healthy tissue from radiation exposure. In this talk, Pedersen discusses the rise of urology – which includes the recent acquisitions of Neotract and NxThera. He also updates listeners on Augmenix’s efforts to secure reimbursement. Finally, the former Boston Scientific exec offers advice to anyone working in a global Medtech company.

John Pedersen

President & CEO

Augmenix

John Pedersen joined Augmenix in 2014. Previously he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, John was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co. John earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University. He currently serves on the Board of Directors of Therakos and Clinical Innovations, two privately held medical device companies.